Sarepta Therapeutics (MEX:SRPT) Cyclically Adjusted FCF per Share: MXN-88.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN306.00
GF Value MXN1,623.60
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Cyclically Adjusted FCF per Share?

Sarepta Therapeutics MEX:SRPT 36 Cyclically Adjusted FCF per Share is MXN-88.35 as of Jun. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN1,623.60 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN32.524. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-88.35 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -8.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sarepta Therapeutics was 13.00% per year. The lowest was -16.60% per year. And the median was -4.00% per year.

As of today (2026-09-11), Sarepta Therapeutics's current stock price is MXN306.00. Sarepta Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-88.35. Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Sarepta Therapeutics  (MEX:SRPT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sarepta Therapeutics Cyclically Adjusted FCF per Share Related Terms


Sarepta Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Cyclically Adjusted FCF per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -102.24

Sarepta Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.71 -105.95 -102.24 -93.47 -88.35

MEX:SRPT vs AUPH, PVLA, MLYS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=32.524/333.9520*333.9520
=32.524

Current CPI (Jun. 2026) = 333.9520.

Sarepta Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -24.755 241.428 -34.242
201612 -31.901 241.432 -44.126
201703 -21.379 243.801 -29.284
201706 -29.057 244.955 -39.614
201709 -19.366 246.819 -26.203
201712 -10.957 246.524 -14.843
201803 -13.635 249.554 -18.246
201806 -38.059 251.989 -50.438
201809 -37.994 252.439 -50.262
201812 -40.046 251.233 -53.231
201903 -43.943 254.202 -57.729
201906 -24.852 256.143 -32.401
201909 -20.456 256.759 -26.606
201912 -45.794 256.974 -59.512
202003 189.797 258.115 245.561
202006 -37.530 257.797 -48.617
202009 -74.149 260.280 -95.137
202012 -51.208 260.474 -65.653
202103 -51.845 264.877 -65.365
202106 -28.716 271.696 -35.296
202109 -34.382 274.310 -41.858
202112 -8.076 278.802 -9.674
202203 -24.355 287.504 -28.290
202206 -17.447 296.311 -19.663
202209 -17.083 296.808 -19.221
202212 -22.318 296.797 -25.112
202303 -44.758 301.836 -49.520
202306 -27.082 305.109 -29.642
202309 -30.468 307.789 -33.058
202312 -12.055 306.746 -13.124
202403 -47.642 312.332 -50.940
202406 -2.629 314.175 -2.794
202409 -21.163 315.301 -22.415
202412 8.476 315.605 8.969
202503 -132.237 319.799 -138.089
202506 40.578 322.561 42.011
202509 -7.916 324.800 -8.139
202512 21.892 324.054 22.561
202603 -30.435 330.213 -30.780
202606 32.524 333.952 32.524

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-88.35 mean?
Sarepta Therapeutics (MEX:SRPT) has a Cyclically Adjusted FCF per Share of MXN-88.35 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Cyclically Adjusted FCF per Share too high?
Sarepta Therapeutics' current Cyclically Adjusted FCF per Share is MXN-88.35. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Cyclically Adjusted FCF per Share compare to AUPH and PVLA?
Sarepta Therapeutics' Cyclically Adjusted FCF per Share of MXN-88.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Cyclically Adjusted FCF per Share is MXN-88.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN1,623.60, compared to a current price of MXN306.00 — trading 81.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-88.35. Sarepta Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Cyclically Adjusted FCF per Share is MXN-88.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN306.00 is trading 81.2% below its estimated GF Value™ of MXN1,623.60. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Cyclically Adjusted FCF per Share: MXN-88.35
  • GF Value™: MXN1,623.60 vs. price of MXN306.00 (81.2% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN306.00
Price
MXN1,623.60
GF Value